Magen-NHL; umschriebene Stadien

53
29 Koch P, del Valle F, Berdel WE et al. Primary gastrointestinal non-Hodgkin's lymphoma II: Combined surgical and
conservative or conservative management only in localized gastric lymphoma. Results of the prospective German multicenter
study (GIT NHL 01/92). J Clin Oncol. 2001;19:3874-3883.
30 Koch P, Willich N, Brockmann J, Tiemann M, and Berdel WE. Localized primary gastric lymphoma (PGL): Treatment
results in 369 patients from two consecutive multicentre studies. Proc Asco. 2001;20:297a.
31 Fischbach W, Dragosics B, Kolve-Gobeler ME et al. Primary gastric B-cell-lymphoma:Results of a prospective multicenter
study. Gastroenterology. 2000;119:1191-1202.
32 Fischbach W. Gastrointestinale Lymphome. Ätiologie, Pathogenese und Therapie. Internist. 2000;41:831-840.
33 Brittinger G, Musshoff K, Bremer K, Meusers P. Grundlagen und allgemeine Probreme der Therapie der Non-Hodgkin-
Lymphome. Internist. 1980;21:493-501.
34 Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP with three intensive chemotherapy
regimens for advanced Non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
35 Bagley CM, DeVita VT, Berad CW, Canellos GP. Advanced lymphosarcoma: Intensive cyclical combination chemotherapy
with cyclophosphamide, vincristine, and prednisone. Ann Intern Med. 1972;76:227-234.
36 Pfreundschuh M, Trümper L, Kloess M et al. 2-Weekly CHOP (CHOP-14): The new standard regimen for patients with
aggressive non-Hodgkin's lymphoma (NHL >60 Years of Age. Blood. 2001;98:725a.
37 Morgner A, Miehlke S, Fischbach W et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure
of Helicobacter pylori. J Clin Oncol. 2001;19:2041-2048.
38 Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-
CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466.
39 Maloney DG, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol. 2002;29 Suppl 2:2-9.
40 McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed
indolent lymphoma: Half of patients respond to a four- dose treatment program. J Clin Oncol. 1998;16:2825-2833.
41 Link BK, Grossbard ML, Fisher RI et al. Phase II pilot study of the safety and efficacy of Rituximab in combination with
CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL. Proc Asco. 1998;17:3a.
42 Vose JM, Link BK, Grossbard ML et al. Phase II study of Rituximab in combination with CHOP chemotherapy in patients
with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-397.
43 Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients
with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
44 Willich NA, Reinartz G, Horst EJ et al. Operative and conservative management of primary gastric lymphoma: Interim
results of a German multicentre study. Int J Radiat Oncol Biol Phys. 2000;46:895-901.
45 Reinartz G, Willich N, Koch P. Strahlentherapie bei primären gastrointestinalen Lymphomen. Chir Gastroenterol.
2002;18:53-59.
46 Reinartz G, Kardels B, Koch P, Willich N. Analysis of failures after whole abdominal irradiation in gastrointestinal
lymphomas. Is prophylactic irradiation of inguinal lymph nodes required Strahlenther Onkol. 1999;175:601-605.
47 Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized
intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
48 Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: A study of 117 cases presenting with
gastrointestinal disease. Cancer. 1978;42:693-707.
49 Seegenschmiedt MH, Sauer H, Müller R-P. Interdisziplinäre Dokumentation von akuten Nebenwirkungen in der Onkologie:
Common Toxicity Criteria (CTC). Forum DKG. 1998;13:178-188.
50 Kloess M, Zeynalova S, Trümper L et al. Effects of G-CSF schedule on leukocyte recovery and infection rate in the
CHOP-14 regimen for elderly patients with aggressive lymphoma. Proc Asco. 2004;22:597.
51 Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoetic colony-stimulating
factors: Evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18:3558-3585.
52 Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-
Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
53 Leventhal BG, Wittes RE. Research methods in clinical oncology. New York: Raven Press; 1988.
54 Buyse M. Randomized designs for early trials of new cancer treatments. Drug Inf J. 2000;34:387-396.
55 Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
56 Peto R, Peto J. Asymptotically efficient rank invariation test procedures. J Roy Stat Soc (A). 1972;135:185-206.
57 Peto R, Pike MC. Design and analysis of clinical trials requiring prolonged observation of each patient (part 1). Br J
Cancer. 1976;34:585-612.
58 Peto R, Pike MC. Design and analysis of clinical trials requiring prolonged observation of each patient (part 2). Br J
Cancer. 1977;35:1-39.
59 Haybittle JL. Significance testing in the comparison of survival curves from clinical trials of cancer treatment. Rec Res
Cancer Res. 1988;111:75-81.
60 Gehan E. A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika. 1965;52:203-223.
61 Prentice RL. Linear rank tests with right censored data. Biometrika. 1978;65:167-197.
Protokollversion 1.2 mit Amendment 2 v. 15.03.2011 (aktiviert 01.06.2011)